Psychopharmacology

, Volume 199, Issue 2, pp 275–289

The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist

  • Sridhar Natesan
  • Greg E. Reckless
  • Karen B. L. Barlow
  • John Odontiadis
  • José N. Nobrega
  • Glen B. Baker
  • Susan R. George
  • David Mamo
  • Shitij Kapur
Original Investigation

Abstract

Rationale

l-Stepholidine, a dopamine D2 antagonist with D1 agonist activity, should in theory control psychosis and treat cognitive symptoms by enhancing cortical dopamine transmission. Though several articles describe its impact on the dopamine system, it has not been systematically evaluated and compared to available antipsychotics.

Materials and methods

We examined its in vitro interaction with dopamine D2 and D1 receptors and compared its in vivo pharmacokinetic profile to haloperidol (typical) and clozapine (atypical) in animal models predictive of antipsychotic activity.

Results

In vitro, l-stepholidine showed significant activity on dopamine receptors, and in vivo, l-stepholidine demonstrated a dose-dependent striatal receptor occupancy (RO) at D1 and D2 receptors (D1 9–77%, 0.3–30 mg/kg; D2 44–94%, 1–30 mg/kg), though it showed a rather rapid decline of D2 occupancy related to its quick elimination. In tests of antipsychotic efficacy, it was effective in reducing amphetamine- and phencyclidine-induced locomotion as well as conditioned avoidance response, whereas catalepsy and prolactin elevation, the main side effects, appeared only at high D2RO (>80%). This preferential therapeutic profile was supported by a preferential immediate early gene (Fos) induction in the nucleus accumbens over dorsolateral striatum. We confirmed its D1 agonism in vitro, and then using D2 receptor, knockout mice showed that l-stepholidine shows D1 agonism in the therapeutic dose range.

Conclusions

Thus, l-stepholidine shows efficacy like an “atypical” antipsychotic in traditional animal models predictive of antipsychotic activity and shows in vitro and in vivo D1 agonism, and, if its rapid elimination does not limit its actions, it could provide a unique therapeutic approach to schizophrenia.

Keywords

l-Stepholidine Antipsychotic D1 and D2 receptor occupancy Schizophrenia Animal models 

Supplementary material

213_2008_1172_MOESM1_ESM.doc (112 kb)
Supplementary Table 1Customized in vitro screening of l-stepholidine by Novascreen® (DOC 112 KB).

References

  1. Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7(Suppl 1):S1–5PubMedCrossRefGoogle Scholar
  2. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708–3719PubMedGoogle Scholar
  3. Aravagiri M, Marder SR (2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) 159:424–431CrossRefGoogle Scholar
  4. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369–377PubMedCrossRefGoogle Scholar
  5. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101PubMedCrossRefGoogle Scholar
  6. Arnt J, Hyttel J, Sanchez C (1992) Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213:259–267PubMedCrossRefGoogle Scholar
  7. Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287:2020–2022PubMedCrossRefGoogle Scholar
  8. Chen LJ, Guo X, Wang QM, Jin GZ (1992) Feed-back regulation of presynaptic D2 receptors blockaded by l-stepholidine and l-tetrahydropalmatine. Acta Pharmacol Sin 13:442–445Google Scholar
  9. Desai RI, Terry P, Katz JL (2005) A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol Biochem Behav 81:843–848PubMedCrossRefGoogle Scholar
  10. Dong ZJ, Chen LJ, Jin GZ, Creese I (1997a) GTP regulation of (−)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum. Biochem Pharmacol 54:227–232PubMedCrossRefGoogle Scholar
  11. Dong ZJ, Guo X, Chen LJ, Han YF, Jin GZ (1997b) Dual actions of (−)-stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum. Life Sci 61:465–472PubMedCrossRefGoogle Scholar
  12. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–174PubMedCrossRefGoogle Scholar
  13. Ellenbroek BA, Zhang XX, Jin GZ (2006) Effects of (−)stepholidine in animal models for schizophrenia. Acta Pharmacol Sin 27:1111–1118PubMedCrossRefGoogle Scholar
  14. Finney DJ (1971) Probit analysis. Cambridge University Press, LondonGoogle Scholar
  15. Floresco SB, Geyer MA, Gold LH, Grace AA (2005) Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull 31:888–894PubMedCrossRefGoogle Scholar
  16. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic, San DiegoGoogle Scholar
  17. Goldman-Rakic PS, Muly EC 3rd, Williams GV (2000) D1 receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295–301PubMedCrossRefGoogle Scholar
  18. Guo H, Yu Y, Xing L, Jin GZ, Zhou J (2002) (−)-Stepholidine promotes proliferation and neuronal differentiation of rat embryonic striatal precursor cells in vitro. Neuroreport 13:2085–2089PubMedCrossRefGoogle Scholar
  19. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245–256PubMedGoogle Scholar
  20. Huang KX, Sun BC, Gonon FG, Jin GZ (1991) Effects of tetrahydroprotoberberines on dopamine release and 3,4-dihydroxyphenylacetic acid level in corpus striatum measured by in vivo voltammetry. Acta Pharmacol Sin 12:32–36Google Scholar
  21. Jentsh JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225CrossRefGoogle Scholar
  22. Jin GZ (1987) (−)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists. Trends Pharmacol Sci 8:81–82CrossRefGoogle Scholar
  23. Jin GZ, Sun BC (1995) Neuropharmacological effects of (−)-stepholidine and its analogues on brain dopaminergic system. Adv Exp Med Biol 363:27–28PubMedGoogle Scholar
  24. Jin GZ, Huang KX, Sun BC (1992) Dual actions of (−)-stepholidine on dopamine receptor subtypes after substantia nigra lesion. Neurochem Int 20(Suppl):175S–178SPubMedCrossRefGoogle Scholar
  25. Jin GZ, Zhu ZT, Fu Y (2002) (−)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol Sci 23:4–7PubMedCrossRefGoogle Scholar
  26. Kane JM, Malhotra A (2003) The future of pharmacotherapy for schizophrenia. World Psychiatry 2:81–86PubMedGoogle Scholar
  27. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625–631PubMedCrossRefGoogle Scholar
  28. Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P (1991) Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 40:657–671PubMedCrossRefGoogle Scholar
  29. Liu J, Guo X, Wang BC, Jin GZ (1999) Increased phosphorylation of DARPP-32 by D1 agonistic action of l-stepholidine in the 6-OHDA-lesioned rat striatum. Acta Physiologica Sinica 51:65–72PubMedGoogle Scholar
  30. McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Fuchs S, Croke DT, Waddington JL (2002) Phenotypic, ethologically based resolution of spontaneous and D2-like vs D1-like agonist-induced behavioural topography in mice with congenic D(3) dopamine receptor “knockout”. Synapse 46:19–31PubMedCrossRefGoogle Scholar
  31. Mo YQ, Jin XL, Chen YT, Jin GZ, Shi WX (2005) Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. Neuropsychopharmacology 30:261–267PubMedCrossRefGoogle Scholar
  32. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006) Dissociation between in vivo occupancy and functional antagonism of dopamine D(2) receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31:1854–1863PubMedCrossRefGoogle Scholar
  33. Odontiadis J, Mackenzie EM, Natesan S, Mamo D, Kapur S, Baker GB (2007) Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 850:544–547PubMedCrossRefGoogle Scholar
  34. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634–636PubMedCrossRefGoogle Scholar
  35. Olsen CM, Duvauchelle CL (2001) Intra-prefrontal cortex injections of SCH 23390 influence nucleus accumbens dopamine levels 24 h post-infusion. Brain Res 922:80–86PubMedCrossRefGoogle Scholar
  36. O’Sullivan GJ, Kinsella A, Sibley DR, Tighe O, Croke DT, Waddington JL (2005) Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions. Synapse 55:201–211PubMedCrossRefGoogle Scholar
  37. O’Sullivan GJ, Kinsella A, Grandy DK, Tighe O, Croke DT, Waddington JL (2006) Ethological resolution of behavioral topography and D2-like vs. D1-like agonist responses in congenic D4 dopamine receptor “knockouts”: identification of D4:D1-like interactions. Synapse 59:107–118PubMedCrossRefGoogle Scholar
  38. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, New YorkGoogle Scholar
  39. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O’Dowd BF, George SR (2007) D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 104:654–659PubMedCrossRefGoogle Scholar
  40. Robbins TW (2005) Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J Comp Neurol 493:140–146PubMedCrossRefGoogle Scholar
  41. Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058–1066PubMedGoogle Scholar
  42. vhRyman-Rasmussen JP, Nichols DE, Mailman RB (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol 68:1039–1048PubMedCrossRefGoogle Scholar
  43. So CH, Varghese G, Curley KJ, Kong MM, Alijaniaram M, Ji X, Nguyen T, O’Dowd BF, George SR (2005) D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol 68:568–578PubMedGoogle Scholar
  44. Terry P, Katz JL (1992) Differential antagonism of the effects of dopamine D1-receptor agonists on feeding behavior in the rat. Psychopharmacology (Berl) 109:403–409CrossRefGoogle Scholar
  45. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1–13PubMedCrossRefGoogle Scholar
  46. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422–429CrossRefGoogle Scholar
  47. Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6:547–558PubMedCrossRefGoogle Scholar
  48. Yang CR, Chen L (2005) Targeting prefrontal cortical dopamine D1 and N-methyl-d-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 11:452–470PubMedCrossRefGoogle Scholar
  49. Zhang ZD, Zhou CM, Jin GZ, Zhang X, Yang L (1990) Pharmacokinetics and autoradiography of [3H] or [14C]stepholidine. Acta Pharmacol Sin 11:289–292Google Scholar
  50. Zhang X, Sun BC, Jin GZ (1997) Atypical neuroleptic properties of l-stepholidine. Science in China (Series C) 40:532–538Google Scholar
  51. Zhang L, Zhou R, Xiang G (2005) Stepholidine protects against H2O2 neurotoxicity in rat cortical neurons by activation of Akt. Neurosci Lett 383:328–332PubMedCrossRefGoogle Scholar
  52. Zhu ZT, Wu WR, Fu Y, Jin GZ (2000) I-stepholidine facilitates inhibition of mPFC DA receptors on subcortical NAc DA release. Acta Pharmacol Sin 21:663–667PubMedGoogle Scholar
  53. Zou LL, Chen Y, Song YY, Jin GZ (1996) Effect of (−)-stepholidine on serum prolactin level of female rats. Acta Pharmacol Sin 17:311–314Google Scholar
  54. Zou LL, Liu J, Jin GZ (1997) Involvement of receptor reserve in D1 agonistic action of (−)-stepholidine in lesioned rats. Biochem Pharmacol 54:233–240PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sridhar Natesan
    • 1
  • Greg E. Reckless
    • 2
  • Karen B. L. Barlow
    • 3
  • John Odontiadis
    • 4
  • José N. Nobrega
    • 3
    • 6
    • 7
    • 8
  • Glen B. Baker
    • 4
  • Susan R. George
    • 5
    • 6
    • 7
  • David Mamo
    • 2
    • 8
  • Shitij Kapur
    • 1
  1. 1.Division of Psychological Medicine and Psychiatry, Institute of PsychiatryKing’s CollegeLondonUK
  2. 2.Schizophrenia Program and the PET CentreCentre for Addiction and Mental Health (CAMH)TorontoCanada
  3. 3.Neuroimaging Research SectionCentre for Addiction and Mental Health (CAMH)TorontoCanada
  4. 4.Department of PsychiatryUniversity of AlbertaEdmontonCanada
  5. 5.Molecular PharmacologyCentre for Addiction and Mental Health (CAMH)TorontoCanada
  6. 6.Department of MedicineUniversity of TorontoTorontoCanada
  7. 7.Department of PharmacologyUniversity of TorontoTorontoCanada
  8. 8.Department of PsychiatryUniversity of TorontoTorontoCanada

Personalised recommendations